25-1839-42

antibody from Invitrogen Antibodies

Targeting: CXCR3 CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

25-1839-42

Provider

Invitrogen Antibodies

Product name

CD183 (CXCR3) Monoclonal Antibody (CEW33D), PE-Cyanine7, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The CEW33D monoclonal antibody reacts with human CD183. CD183, also known as CXCR3, is a G protein-coupled chemokine receptor that interacts with ligands CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (I-TAC). Strongly associated with type 1 immunity, CD183 is induced in naive T cells upon activation and remains upregulated in T helper type (Th)1 cells, CD8 effector cells, NK cells and NKT cells. CD183-ligand interactions mediate infiltration of inflamed tissues in normal type 1 immune responses as well as in many inflammatory and autoimmune diseases. CD183 is also expressed on some B cells and plasmacytoid DC. Applications Reported: This CEW33D antibody has been reported for use in flow cytometric analysis. Applications Tested: This CEW33D antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.5 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Light sensitivity: This tandem dye is sensitive to photo-induced oxidation. Please protect this vial and stained samples from light. Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-822-49) (100 µL of cell sample + 100 µL of IC Fixation Buffer) or 1-step Fix/Lyse Solution (Product # 00-5333-54) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone specific performance should be determined empirically. Excitation: 488-561 nm; Emission: 775 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

CEW33D

Vial size

100 Tests

Concentration

5 µL/Test

Storage

4° C, store in dark, DO NOT FREEZE!

References

Submitted references

Mucosal-associated invariant T cell responses differ by sex in COVID-19.

Yu C, Littleton S, Giroux NS, Mathew R, Ding S, Kalnitsky J, Yang Y, Petzold E, Chung HA, Rivera GO, Rotstein T, Xi R, Ko ER, Tsalik EL, Sempowski GD, Denny TN, Burke TW, McClain MT, Woods CW, Shen X, Saban DR
Med (New York, N.Y.) 2021 Jun 11;2(6):755-772.e5

---

Subsets of human CD4(+) regulatory T cells express the peripheral homing receptor CXCR3.

Hoerning A, Koss K, Datta D, Boneschansker L, Jones CN, Wong IY, Irimia D, Calzadilla K, Benitez F, Hoyer PF, Harmon WE, Briscoe DM
European journal of immunology 2011 Aug;41(8):2291-302

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Normal human peripheral blood cells were stained with CD3 Monoclonal Antibody, eFluor 450 (Product # 48-0037-42) and Mouse IgG1 kappa Isotype Control, PE-Cyanine7 (Product # 25-4714-80) (left) or CD183 (CXCR3) Monoclonal Antibody, PE-Cyanine7 (right). Cells in the lymphocyte gate were used for analysis.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

3 Co-expression of CXCR3 with FOXP3, CTLA-4 and CD39 on CD4 + T cells. (A and B) Representative flow cytometry plots illustrating co-expression of CXCR3 and CD25 on (A) the CD4 + FOXP3 + T-cell subset and (B) the CD4 + CTLA-4 + subset. Staining with isotype control antibodies is shown on the right of each dot plot. (C) Median, 25th and 75th percentile and range of CXCR3 expression on CD4 + FOXP3 + or CD4 + CTLA-4 + subsets. (D and E) Representative flow cytometry plots of CXCR3 expression on (D) double positive FOXP3 + CTLA-4 + cells and (E) FOXP3 + CD39 + cells after gating on CD4 + cells. The box plot on the right of each panel illustrates median, 25th and 75th percentile and range of expression in multiple experiments. (F) Fold difference (mean+SEM) in mRNA expression for Tbet in sorted populations of CD4 + CD25 hi CXCR3 pos cells (white bars) or CD4 + CD25 hi CXCR3 neg Tregs (black bars). Expression was evaluated in unactivated Tregs (left panel) or in Tregs following 6 h activation with anti-CD3/anti-CD28 (right panel). Representative of n =3 experiments with similar results.